^
    6ms
    NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) (clinicaltrials.gov)
    P2, N=199, Completed, NFlection Therapeutics, Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    NF1 (Neurofibromin 1)
    |
    NFX-179
    1year
    NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) (clinicaltrials.gov)
    P2, N=199, Active, not recruiting, NFlection Therapeutics, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Feb 2023 --> Sep 2023 | Trial primary completion date: Jan 2023 --> Sep 2023
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    NF1 (Neurofibromin 1)
    |
    NFX-179
    over2years
    NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) (clinicaltrials.gov)
    P2, N=168, Recruiting, NFlection Therapeutics, Inc. | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    NF1 (Neurofibromin 1)
    |
    NFX-179
    over2years
    NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) (clinicaltrials.gov)
    P2, N=168, Not yet recruiting, NFlection Therapeutics, Inc.
    Clinical • New P2 trial
    |
    NF1 (Neurofibromin 1)
    |
    NFX-179
    over2years
    NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) (clinicaltrials.gov)
    P2a, N=48, Completed, NFlection Therapeutics, Inc. | Recruiting --> Completed
    Trial completion
    |
    NF1 (Neurofibromin 1)
    |
    NFX-179